KIYATEC leverages its proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company's Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for its investigational drug candidates across the majority of solid tumor types.
Market
Cancer Drug Development
Location
Greenville,
South Carolina,
USA
Coinvestors
Bruker Corporation, LabCorp, Seae Ventures, VentureSouth